Acadian Asset Management LLC Raises Shares in Organon & Co. (NYSE:OGN)

Acadian Asset Management LLC grew its position in Organon & Co. (NYSE:OGN – Free Report) by 2,103,633.3% in the second quarter, Holdings Channel.com reports. The institutional investor owned 63,112 shares of the company’s stock after buying an additional 63,109 shares during the period. Acadian Asset Management LLC’s holdings in Organon & Co. were worth $1,306,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc increased its stake in Organon & Co. by 200.2% in the second quarter. Versant Capital Management Inc now owns 1,207 shares of the company’s stock valued at $25,000 after purchasing an additional 805 shares in the last quarter. Fidelis Capital Partners LLC acquired a new stake in shares of Organon & Co. in the first quarter worth approximately $43,000. Tompkins Financial Corp raised its stake in shares of Organon & Co. by 450.7% in the first quarter. Tompkins Financial Corp now owns 2,412 shares of the company’s stock worth $45,000 after buying an additional 1,974 shares in the last quarter. Atlas Capital Advisors LLC raised its stake in shares of Organon & Co. by 2,236.5% during the second quarter. Atlas Capital Advisors LLC now owns 2,243 shares of the company’s stock worth $46,000 after buying an additional 2,147 shares during the last quarter. Finally, Hexagon Capital Partners LLC increased its stake in shares of Organon & Co. by 123.9% in the first quarter. Hexagon Capital Partners LLC now owns 2,628 shares of the company’s stock worth $49,000 after purchasing an additional 1,454 shares during the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s shares.

Analysts set new price targets

Separately, JPMorgan Chase & Co. reduced Organon & Co. from a “neutral” rating to an “underweight” rating and boosted their target price for the stock from $18.00 to $20.00 in a research note on Friday, September 6th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $22.17, based on data from MarketBeat.com.

Get the latest report on Organon & Co.

Trading Organon & Co. increased by 0.9%

Shares of OGN stock opened at $20.47 on Monday. The company’s fifty day moving average price is $21.02 and its 200 day moving average price is $20.03. Organon & Co. has a 1 year low of $10.84 and a 1 year high of $23.10. The firm has a market cap of $5.26 billion, a PE ratio of 5.00, a P/E/G ratio of 0.89 and a beta of 0.85. The company has a debt-to-equity ratio of 60.05, a current ratio of 1.64, and a quick ratio of 1.17.

Organon & Co. (NYSE:OGN – Get Your Free Report ) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.04. Organon & Co. had a negative return on equity of 840.29% and a net margin of 15.76%. The firm had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.61 billion. In the same quarter last year, the company posted earnings of $1.31 per share. Organon & Co.’s quarterly revenue they decreased by 0.1% year-on-year. As a group, sell-side analysts estimate that Organon & Co. will post 4.14 EPS for the current fiscal year.

Organon & Co. announces dividends

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 12th. Investors of record on Friday, August 16th were issued a dividend of $0.28 per share. This represents a dividend of $1.12 on an annualized basis and a yield of 5.47%. The ex-dividend date of this dividend was Friday, August 16. Dividend payout rate organized by Organon & Co. it is currently 27.38%.

Organon & Co. Company Profile

(Free report)

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices in women’s health in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, a progestin and estrogen used as a daily pill to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproductive technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix acetate injectable, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.

Featured stories

Want to see what other hedge funds own OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Organon & Co. (NYSE:OGN – Free Report).

Get news and reviews for Organon & Co. daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Organon & Co. and affiliates with MarketBeat.com’s FREE daily email newsletter.